Keen Eye and Iris Pharma Team up to Bring Artificial Intelligence in Ophthalmology Studies
Keen Eye , a French technology company specialized in image analysis for the life science industry, announced today a strategic partnership agreement with Iris Pharma , a world-wide leading ophthalmology-focused contract research organization (CRO) that offers preclinical and clinical drug / device development services. The partnership aims at providing Iris Pharma artificial intelligence (AI) applications to make assays faster, more reliable and more efficient.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181009005491/en/
For Sylvain Berlemont, Founder & CEO of Keen Eye, “We are very happy to team up and bring our expertise in computer vision to Iris Pharma. Through this partnership, we are expecting to contribute to the most challenging image-based assays to better fight eye diseases”.
For Yann Quentric, President of Iris Pharma, « The advanced AI technology of Keen Eye allows us to optimize the performance of the bioimaging analysis during the preclinical ophthalmic drug development, and in the future for clinical development. Their solution is faster than classical methods, robust and reliable, erasing inter-individual variability, improving Iris Pharma and its customers ability to develop ocular innovative products. »
About Keen Eye
Seeing Beyond Pixels
Founded in 2013, Keen Eye is a technology company based in Paris; aiming
at bringing AI into every laboratory for the benefit of biologists,
pathologists and patients. The company is building decision-support and
GLP-compliant image analysis solutions to accelerate the development of
new therapies with better, faster and accurate analytics.
Keen Eye develops web-based solutions which help biologists and pathologists that usually spend thousands of hours on the microscope. Among others, Keen Eye delivers image quantification applications using its deep learning technology.
For more information: www.keeneye.tech
About Iris Pharma
A leading CRO dedicated to ophthalmology, Iris Pharma helps clients around the world navigate every stage of the drug and device development process – including in vivo screening, proof of concept, ocular efficacy, GLP preclinical studies, bioanalysis, clinical trials, and marketing surveys. This CRO has expertise in all ophthalmic indications, and supports clients ranging from small start-ups to large pharmaceutical companies in moving forward products that directly or indirectly affect eye health.
For more information: www.iris-pharma.com
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
CA-XPRIZE22.10.2018 19:52 | pressemeddelelse
Grand Prize Winner in $1.75M Water Abundance XPRIZE Announced at XPRIZE Visioneering 2018
IL-GILEAD/GALAPAGOS22.10.2018 19:17 | pressemeddelelse
Positive Trial Results with Filgotinib in Psoriatic Arthritis and Ankylosing Spondylitis Both Published in The Lancet
INSIDE-SECURE/FIRST-DATA22.10.2018 17:38 | pressemeddelelse
First Data Polska Deploys Inside Secure’s Mobile Payment Technology To Securely and Easily Connect to Mastercard and Visa
PA-PMI22.10.2018 16:02 | pressemeddelelse
PMI Launches Search for Next President and CEO
TX-E2OPEN22.10.2018 15:45 | pressemeddelelse
E2open to Acquire INTTRA, Adding the World’s Leading Ocean Shipping Network and Software Provider, Creating an Integrated Global Supply Chain and Logistics Operating Network
RAREMARK22.10.2018 14:02 | pressemeddelelse
Patient-Data Platform Raremark Raises £3m to Enable Precision Medicine in Rare Disease
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum